Episodes
How Biotech Startups Are Fixing Their Broken Supply Chains
Biotech startups often fail not because their science is bad, but because they cannot manufacture it at scale. In this episode, Lucas and Luna explore the hidden bottleneck of cold-chain logistics and why companies like Moderna had to build their own manufacturing infrastructure from scratch. We examine how a single broken link in the supply chain can derail years of research, the rise of vertical integration in life sciences, and what founders must do to protect their product before Phase…
The Biotech Patent Cliff Challenge
Lucas and Luna explore the looming expiration of key biotech patents in late 2026, examining how startups are repositioning their pipelines to survive the loss of exclusivity. They analyze specific strategies like lifecycle management, combination therapies, and pivot points into rare disease markets, using real-world examples from established pharma giants and emerging ventures. The conversation highlights the financial pressure on companies facing a cliff edge and offers insights for…
Biotech Startups And The Clinical Trial Shortage Crisis
In October 2026, the biotech sector faces a paradoxical bottleneck: while capital has returned to life sciences and discovery pipelines are richer than ever, the physical infrastructure to test these drugs is critically constrained. We examine how the post-pandemic normalization of clinical trial sites has created a severe shortage of patient recruitment capacity and specialized lab space, forcing startups to bid against legacy pharma giants for limited enrollment slots. This episode explores…
The Biotech Valuation Trap
Biotech startups often hit a wall not because their science fails, but because they misprice the bridge to commercialization. Lucas and Luna examine how the 'Valuation Gap' between late-stage venture capital and public market expectations creates a death spiral for promising drugs. They break down why recent FDA approvals have led to stock drops, the hidden costs of Phase Three trials, and why smart founders are now choosing strategic partnerships over IPOs. This episode explores the specific…
How Biotech Startups Navigate Regulatory Moats
We look at how emerging biotech firms use regulatory strategy as a competitive weapon rather than a compliance burden. With the FDA’s Real-World Evidence framework gaining traction by October 2026, startups are leveraging patient data to accelerate approvals. We explore specific case studies of companies that turned clinical trial constraints into strategic advantages, avoiding common pitfalls in the approval pipeline. #BiotechStartups #FDAApprovals #RegulatoryStrategy #RealWorldEvidence…
How Biotech Startups Navigate Patent Thickets
We examine the strategic pivot of a leading gene therapy firm as it faces an expanding web of overlapping intellectual property claims. Lucas and Luna break down why traditional patent protection is no longer enough for life sciences startups in late-stage development, and how companies are using regulatory exclusivity and novel licensing structures to protect their pipeline assets. This episode explores the specific mechanics of patent thickets in CRISPR-based therapies and what founders must…
Biotech Startups And The Regulatory Moat
We explore how early-stage life science companies are building defensible competitive advantages not through proprietary algorithms, but through deep regulatory strategy. Using the FDA's Breakthrough Therapy designation as a lens, we examine why some biotech firms accelerate approval timelines while others stall in clinical death valleys. Lucas and Luna break down the economics of regulatory moats, analyzing specific case studies where strategic engagement with the FDA transformed valuation…
How Biotech Startups Win Big Pharma Partnerships
Most biotech founders think the hard part is discovering a molecule. The real bottleneck is convincing large pharmaceutical companies to buy in before Phase Two data exists. In this episode, we examine how early-stage life sciences startups structure value-acknowledgment deals and milestone payments to bridge the gap between lab results and commercial scale. We look at why big pharma prefers licensing over acquiring now, the specific risks of out-licensing your own pipeline, and how founders…
The Biotech Exit Premium Puzzle
We look at why biotech startups are selling for less than their R&D costs suggest, using a specific recent deal structure to explain the shift from pipeline value to cash flow reality. Lucas and Luna break down how investor patience has evaporated since early 2024, leaving founders with a choice between dilution or discount. We examine one mid-cap company that pivoted its go-to-market strategy to secure a premium valuation, contrasting it with peers who waited too long for regulatory clarity.…
The Biotech Lab Rat Economy
We explore how biotech startups are shifting from the expensive, slow traditional animal testing model to high-throughput organ-on-a-chip platforms. Using a specific case of a cardiovascular drug candidate that failed in Phase Two but showed promising safety signals in human cell models, we examine why this pivot matters for de-risking clinical trials and attracting venture capital in late October two thousand twenty six. #OrganOnAChip #BiotechStartups #DrugDiscovery #LabRats #ClinicalTrials…
How Biotech Startups Fix Their Own Broken Supply Chains
We drill into the operational reality of vertical integration in life sciences. Lucas and Luna examine why startups are no longer outsourcing manufacturing to third-party contract organizations but building internal capacity instead. We look at the specific capital trade-offs, the technical hurdles of scaling bioreactors, and the strategic advantage of controlling your own production from Phase Two through commercial launch. #BiotechStartups #VerticalIntegration #LifeSciences…
How Biotech Startups Monetize Patient Data
We examine the emerging revenue model where biotech startups license anonymized real-world patient data rather than selling drug assets alone. Lucas and Luna break down how companies like Flatiron Health have shifted from clinical trial support to independent data analytics firms, and what this means for startup valuation in October twenty twenty-six. #BiotechStartups #RealWorldData #PatientDataMonetization #FlatironHealth #LifeSciencesBusiness #DigitalHealth #DataAnalytics #PharmaPartnerships…
Biotech Startups Navigating The Clinical Trial Death Valley
Episode 206 explores the 'Clinical Trial Death Valley' where promising biotech candidates stall not because of bad science, but due to operational bottlenecks and misaligned incentives. Lucas and Luna dissect how startups are leveraging decentralized trial models and real-world evidence to bridge the gap between Phase One success and regulatory approval. We examine specific data points on patient retention rates, cost overruns in mid-stage trials, and the strategic shifts occurring as of…
The Hidden Cost of Biotech Clinical Trials
We explore how life sciences startups are navigating the clinical trial death valley by leveraging decentralized technology and real-world data to cut costs. This episode examines specific strategies for reducing patient attrition and streamlining site selection, offering actionable insights for founders and investors in the biotech sector. #BiotechStartups #ClinicalTrials #DrugDiscovery #FDAApprovals #LifeSciences #VentureCapital #HealthTech #PatientRecruitment #DecentralizedTrials…
Biotech Startups And The Valuation Reset
We look at how biotech founders are navigating the post-2021 capital correction. With interest rates still elevated in October two thousand twenty-six, early-stage deals have shifted from growth-at-all-costs to path-to-profitability. We examine a specific case study of a gene therapy startup that pivoted its clinical strategy to extend runway without diluting shareholders. Lucas and Luna break down the new metrics investors now demand before writing checks for Series A rounds. #BiotechValuation…
The Clinical Trial Death Valley Problem
We talk about the specific financial trap known as 'Clinical Trial Death Valley' that traps promising biotech startups between Phase One success and Phase Three funding. Using the case of a hypothetical but representative gene therapy firm, we break down why capital markets are punishing these companies right now in October two thousand twenty-six, and how venture debt and strategic partnerships are becoming the only lifelines for drug developers who have proven their science but run out of…
Why Biotech Startups Fail At Scale
We examine the specific operational gap that kills promising biotech companies after their initial discovery phase. Using a hypothetical mid-stage gene therapy firm as our anchor, we break down why scaling manufacturing and clinical operations is fundamentally different from early research. We discuss the hidden costs of quality control, the talent war for experienced plant managers, and how venture debt structures are changing to address these non-revenue milestones. If you are building or…
How Biotech Startups Use Real World Data To Speed Trials
Episode 201 explores how life sciences startups are bypassing traditional clinical trial delays by integrating real world data into early development. We examine the specific mechanics of using electronic health records and wearable device telemetry to de-risk Phase Two decisions before committing to expensive randomized controlled trials. Lucas and Luna break down a concrete case where a small biotech firm used historical patient cohorts to refine inclusion criteria, cutting their recruitment…
The Biotech Capital Crunch And The Rise Of Venture Debt
With the venture capital market tightening in September 2026, early-stage biotech startups are facing a harsh new reality. We explore how companies like Arbutus Biopharma and smaller peers are pivoting from traditional equity financing to venture debt instruments to extend their runway. Lucas and Luna break down the mechanics of bridge loans, the hidden costs of dilution avoidance, and why the current valuation winter is forcing founders to choose between speed and survival. This episode looks…
Why Biotech Startups Are Betting on Rare Diseases
We examine how small-cap biotech firms are shifting capital from crowded oncology targets to ultra-rare genetic disorders. Lucas and Luna break down the economics of orphan drug designations, the specific regulatory incentives driving this pivot, and why the market is finally rewarding focused science over broad platform hype. We look at a recent case study of a startup that secured FDA approval for a condition affecting fewer than one in two million people, analyzing their trial design…
The Silent Killer of Biotech Deals
We break down the critical, often overlooked bottleneck in biotech startups: the transition from discovery to clinical manufacturing. Lucas and Luna examine why most promising drug candidates fail not because of efficacy, but because they cannot be scaled for human trials. We look at the specific engineering challenges of cell therapy production, the rise of continuous processing, and how early-stage founders are integrating GMP readiness into their very first lab protocols to avoid the…
How AI Is Rewriting Drug Discovery Pipelines
We look at how deep learning models are shifting biotech from trial-and-error to predictive design. Using AlphaFold and modern generative chemistry as anchors, we examine the real impact on discovery timelines, the data quality problem that still haunts startups, and what this means for valuation in late September 2026. It is not magic, it is a new layer of infrastructure. #BiotechInnovation #ArtificialIntelligence #DrugDiscovery #AlphaFold #GenerativeChemistry #LifeSciences #VentureCapital…
The Hidden Cost of Biotech Clinical Trials
Biotech startups are burning through cash at unprecedented rates, but the real bottleneck isn't just funding—it's the operational friction in clinical trials. We break down how leading life sciences companies are using digital health technologies and decentralized trial models to cut patient recruitment time by nearly half. Lucas and Luna explore why this shift matters for drug discovery timelines, regulatory approval speeds, and ultimately, who gets access to new medicines faster. From remote…
The Biotech Supply Chain Black Box
We talk to operators about the hidden bottleneck in drug development: cell and gene therapy manufacturing. With global demand for mRNA vaccines and CAR-T treatments outpacing capacity, startups are betting on modular, single-use bioreactors to scale faster than traditional steel-tank facilities. We examine why this shift matters for patient access and how it changes the risk profile for early-stage developers. #BiotechSupplyChain #CellAndGeneTherapy #ManufacturingBottleneck…
Biotech Startups Mastering Clinical Trial De-Risking
In this episode of Biotech Business with Fexingo, Lucas and Luna examine how early-stage life sciences companies are shifting their strategy from pure discovery to clinical de-risking. We look at the specific mechanics of using real-world evidence and adaptive trial designs to secure Series B funding in today's valuation environment. The conversation centers on a recent deal structure involving a rare disease platform that leveraged patient registry data to shorten Phase One timelines by nearly…
How Biotech Startups Use Real-World Data To Speed Trials
Biotech startups are bypassing traditional recruitment bottlenecks by integrating real-world data from wearables and electronic health records into clinical trials. Lucas and Luna examine how companies like Tempus and Flatiron Health are turning passive patient data into active trial assets, reducing enrollment time by half while raising questions about privacy and regulatory acceptance at the FDA. #RealWorldData #ClinicalTrials #BiotechStartups #DigitalHealth #FDAApproval #WearableTech…
Biotech Startups And The CMO Bottleneck
In this episode of Biotech Business with Fexingo, Lucas and Luna explore the critical manufacturing crisis facing life sciences startups. With clinical trials failing at unprecedented rates in the current market environment, the bottleneck is no longer discovery—it's scale-up. We examine how contract manufacturing organizations are struggling to meet demand, the hidden costs of delayed timelines, and why startups are pivoting toward vertical integration. From GMP facility constraints to the…
The Biotech Patent Cliff And The Race To License First
With the foundational CRISPR patents facing expiration in late 2026, Lucas and Luna break down how life sciences startups are pivoting from proprietary moats to open-access licensing models. They examine the specific financial mechanics of this shift, using a hypothetical but realistic mid-stage gene therapy firm as a case study to show why speed-to-market now outweighs exclusive IP control. This episode explores the strategic trade-offs between building a fortress around a single target versus…
Biotech Startups Navigating The Valuation Winter
In this episode, we examine the structural shift in biotech financing as venture capital tightens its grip on early-stage drug discovery. With interest rates holding steady into September of two thousand twenty-six, startups are forced to choose between dilutive equity raises and expensive venture debt. We break down how companies like Intellia Therapeutics and Beam Therapeutics are adjusting their runway strategies, focusing on milestone-driven tranches rather than blunt valuations. Lucas and…
How Biotech Startups Are Solving The Protein Degradation Problem
We’re looking at the operational reality of protein degraders, specifically PROTACs, in early-stage biotech. While the science is proven, the manufacturing bottleneck remains severe. Lucas and Luna break down why scaling production for these binary molecules is so different from traditional small-molecule drugs, focusing on the specific supply chain constraints facing startups like Arvinas and C4 Therapeutics. We explore how these companies are navigating CMO partnerships to move from lab bench…
Biotech Startups And The CMO Bottleneck
While AI and gene editing grab headlines, biotech startups face a silent killer: the lack of skilled Contract Manufacturing Organizations. We explore how the shortage of CMO capacity is delaying approvals, inflating costs, and forcing early-stage companies to pivot their business models entirely in late 2026. #BiotechStartups #ContractManufacturing #CMOBottleneck #DrugDevelopment #FDAApprovals #VentureCapital #SupplyChainRisk #LifeSciences #BusinessStrategy #TechInvesting #PharmaIndustry…
Biotech Startups Mastering In Vivo Gene Delivery
In vivo gene editing promises to cure disease by fixing DNA inside the body, but delivery remains the bottleneck. We examine how startups are solving this with lipid nanoparticles and viral vectors, using specific examples from recent clinical trials in September 2026. Learn why getting the therapeutic payload to the right cell is harder than designing the edit itself. #BiotechStartups #InVivoGeneEditing #GeneDelivery #LipidNanoparticles #CRISPR #mRNATherapeutics #ClinicalTrials #FDAApprovals…
Biotech Startups Mastering In Vivo Gene Delivery
This episode explores how biotech startups are bypassing traditional drug delivery bottlenecks by engineering viral vectors for in vivo gene therapy. We examine the specific mechanics of lipid nanoparticles and adeno-associated virus capsids, focusing on the recent breakthroughs in tissue targeting that allow treatments to reach the liver, eye, and brain without systemic toxicity. Lucas and Luna discuss the capital intensity of vector manufacturing, the regulatory hurdles faced by companies…
How Biotech Startups Are Winning With Platform Models
We look at how emerging biotech firms are shifting from single-product bets to reusable discovery platforms, using the specific case of Recursion Pharmaceuticals and its partnership with Merck. Lucas and Luna break down why investors are finally rewarding platform durability over binary trial outcomes, and what this means for drug pricing and pipeline depth in late September twenty twenty six. #BiotechStartups #DrugDiscovery #PlatformTechnology #RecursionPharmaceuticals #MerckAndCo…
The Quiet Rise of In Vivo Gene Editing
We explore how in vivo gene editing is shifting from laboratory curiosity to commercial reality. While earlier episodes covered base editing and CRISPR in general, this conversation focuses on the logistical and biological hurdles of delivering genetic cargo directly into human organs like the liver and heart. We look at lipid nanoparticles as the primary delivery vehicle, examining why they work for some tissues but fail for others. The discussion centers on the specific challenge of targeting…
How Biotech Startups Are Winning With Platform Models
Most biotech startups fail because they bet on a single molecule instead of a reusable engine. This episode explores how platform technologies like CRISPR delivery systems and continuous manufacturing are changing the economics of drug discovery. We look at specific examples of companies that built scalable infrastructure rather than just one-off assets, and why investors are shifting capital from asset-heavy bets to platform-first strategies in this quarter. #BiotechStartups…
The Biotech Supply Chain Bottleneck
In this episode of Biotech Business, Lucas and Luna dissect the hidden crisis in life sciences: the critical shortage of single-use bioreactor bags. With global demand outpacing supply, startups are facing lead times of up to six months for essential consumables. We explore how companies like Sartorius and Merck KGaA are expanding capacity, why secondary suppliers are struggling with quality control, and what this means for drug development pipelines in late 2026. The conversation also covers…
How Biotech Startups Are Solving The Protein Degradation Problem
We dive into the mechanics and economics of molecular glues and PROTACs, exploring how startups are moving beyond traditional small molecules to selectively tag proteins for destruction. We look at specific clinical progress in targeting previously undruggable disease drivers, the unique manufacturing hurdles of complex biologics, and why this technology is reshaping venture capital valuations in late-stage biotech as of September 2026. #BiotechStartups #DrugDiscovery #ProteinDegraders…
Biotech Startups Navigating The Valuation Winter
In this episode of Biotech Business, Lucas and Luna dissect the structural shift in life sciences financing as September 2026 arrives. With venture capital drying up for early-stage discovery, startups are pivoting from speculative moonshots to asset-light partnerships and strategic mergers. We examine how companies like Gilead Sciences and Merck are acquiring promising pipelines instead of funding them from scratch, and what this means for the future of independent biotech innovation.…
The Biotech Valuation Winter And The Rise Of Venture Debt
In September 2026, the biotech sector is navigating a sharp divergence between clinical success and capital access. While regulatory approvals for novel therapies continue at a steady clip, traditional venture equity has grown scarce and expensive. This episode examines how startups are pivoting to venture debt and milestone-based financing to extend their runway without diluting early shareholders. We look at the specific mechanics of non-dilutive funding, the rising role of specialized…
Why Biotech Patents Are Becoming a Nightmare
This episode examines the growing legal and financial crisis in life sciences: the patent cliff. With major blockbuster drugs facing expiration, startups are struggling to secure new intellectual property protection for novel mechanisms like targeted protein degradation and next-generation gene therapies. We explore how the shift from molecule-first to mechanism-first R&D is clashing with outdated patent frameworks, creating uncertainty for investors and developers alike. #BiotechPatents…
How Biotech Startups Use Organoids for Drug Testing
Episode 177 of Biotech Business with Fexingo explores how organoids are replacing traditional animal models in early-stage drug discovery. Lucas and Luna discuss the specific advantages of three-dimensional cell cultures, including patient-specific disease modeling and reduced reliance on rodent trials. They examine real-world applications in neurology and oncology, highlighting why this shift matters for faster FDA approvals and more predictable clinical outcomes. The conversation covers…
How Biotech Startups Use Gene Editing for Rare Diseases
We look at the specific mechanics of base editing and prime editing in early-stage biotech, using Vertex Pharmaceuticals as a durable example of how precise genetic fixes are turning previously untreatable conditions into manageable ones. The conversation explores why these tools matter more than broad CRISPR screens for rare disease patients, the regulatory hurdles facing FDA approvals, and the economic reality of pricing one-time cures versus lifetime therapies. We also touch on the supply…
Biotech Startups Tackle Drug Development Through AI Simulation
We look at how computational biology is reshaping the earliest stages of drug discovery, focusing on the shift from wet-lab screening to in silico modeling. With Lucas and Luna, we examine why this matters for pipeline efficiency, the specific role of generative AI in protein design, and what investors should watch for as these startups move from simulation to clinical reality. This is a deep dive into the technology that could cut years off development timelines. #BiotechInnovation…
The Hidden Cost of Biotech Clinical Trial Failures
Every year, biotech startups spend billions on clinical trials that ultimately fail to prove their drugs work. In this episode of Biotech Business, Lucas and Luna break down the specific financial mechanics behind these failures, focusing on the concept of 'trial inflation' and how early-phase data gaps lead to catastrophic late-stage losses. We examine a hypothetical but realistic case study of a metabolic disease startup that underestimated patient recruitment complexity, leading to a…
How Biotech Startups Use Synthetic Biology for Sustainable Materials
This episode explores how synthetic biology startups are moving beyond medicine to create sustainable industrial materials. We examine the specific case of MycoWorks, which uses fungal mycelium to grow leather alternatives that compete with traditional tanning processes. Lucas and Luna discuss the economics of bio-fabrication, the energy savings compared to animal agriculture, and the regulatory hurdles facing novel biological manufacturing. We also look at Ginkgo Bioworks' platform approach to…
How Biotech Startups Use Protein Degraders to Target Disease
In this episode, Lucas and Luna dive into the world of targeted protein degradation, a technique that's reshaping how biotech startups approach drug discovery. Instead of just blocking a disease-causing protein, these degraders, like PROTACs and molecular glues, tag it for the cell's own recycling system. Lucas explains the science with a concrete example: a protein called ARV-110, developed by Arvinas, which showed promise in treating prostate cancer. He walks through how these molecules work…
How Biotech Startups Use AI to Predict Drug Toxicity
Lucas and Luna explore how biotech startups are using artificial intelligence to predict drug toxicity earlier in development, potentially saving billions and avoiding late-stage failures. They discuss the limitations of animal models, the rise of in silico toxicology, and a specific case where AI flagged a cardiotoxicity risk that traditional methods missed. The episode highlights the balance between speed and safety, and what this means for patients, regulators, and the future of drug…
How Biotech Startups Use AlphaFold for Protein Folding
In this episode, Lucas and Luna explore how biotech startups are leveraging AlphaFold, the AI system for protein structure prediction, to accelerate drug discovery. They discuss the breakthrough moment in 2020 when AlphaFold solved the protein folding problem, the subsequent release of the AlphaFold Protein Structure Database with over 200 million predicted structures, and how startups are now using these predictions to design drugs, understand disease mechanisms, and identify new therapeutic…
How Biotech Startups Use AI to Design Better Antibodies
In this episode of Biotech Business, Lucas and Luna explore how startups are using artificial intelligence to design antibodies that bind more precisely to their targets. They discuss the shift from traditional hybridoma screening to computational design, highlighting companies like AbCellera and IONTAS, and explain how AI reduces the trial-and-error in early drug discovery. Learn about the concept of antibody 'developability' and how machine learning predicts which candidates will succeed not…
Showing the latest 50 episodes. The full archive of 218 is on Apple Podcasts, Spotify and every major podcast app — or via the RSS feed above.